Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

Immune checkpoint inhibitors (ICIs) are first line treatment for advanced lung cancer. Tobacco use is a shared risk factor for lung cancer and chronic obstructive pulmonary disease (COPD). Although many patients with COPD and lung cancer receive ICIs, the impact of ICIs on COPD is unknown. Here, we...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Anet Greib, Songzhu Zhao, Michelle Ploch, Jonathan Henricks, Robert Easterling, Meghana Moodabagil, Gabrielle Lopez, Mingjia Li, Evelyn G. Goodyear, John Sharp, Asrar Alahmadi, Jacob Kaufman, Regan Memmott, Kai He, Peter Shields, David P. Carbone, Gregory A. Otterson, Carolyn J. Presley, Lai Wei, Dwight H. Owen, Kevin Ho
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Taylor & Francis Group 2025-12-01
Reeks:	OncoImmunology
Onderwerpen:	Chronic obstructive pulmonary disease (COPD) immune checkpoint inhibitors (ICI) lung cancer
Online toegang:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2469375
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!